Table 3.

Associations With Any Meningococcal Carriage

Characteristic	Bivariate Prevalence Ratioa	P Value	Multivariable Prevalence Ratioa,b	P Value
Round
1	1.0		1.0
2	1.1 (0.9, 1.2)	.351	0.7 (0.4, 1.1)	.111
3	0.8 (0.7, 1.0)	.033	0.6 (0.4, 0.9)	.013
4	0.9 (0.8, 1.1)	.261	0.6 (0.4, 1.0)	.062
Graduation year
2019	1.0 (0.7, 1.4)	.985	1.1 (0.8, 1.7)	.503
2018	1.0		1.0
2017	1.6 (1.3, 1.9)	<.001	1.5 (1.2, 1.9)	<.001
2016	1.3 (1.0, 1.6)	.067	1.2 (1.0, 1.5)	.107
2015	0.9 (0.7, 1.2)	.515	0.9 (0.7, 1.2)	.608
Graduate student	0.7 (0.1, 4.2)	.670	0.8 (0.2, 4.1)	.837
Live on campus	0.9 (0.8, 1.1)	.544	—	—
Male	1.5 (1.3, 1.8)	<.001	1.3 (1.1, 1.5)	<.001
Recent antibiotic usec	0.4 (0.3, 0.6)	<.001	0.4 (0.3, 0.6)	<.001
Recent upper respiratory symptomsd	1.1 (1.0, 1.2)	.064	—	—
Smokerc	1.5 (1.3, 1.7)	<.001	1.3 (1.1, 1.5)	.003
Second-hand smokec	1.2 (1.1, 1.4)	.006	1.0 (0.8, 1.1)	.610
Visit bars, clubs, parties ≥1×/wk	1.9 (1.6, 2.2)	<.001	1.8 (1.5, 2.1)	<.001
Received MenACWY vaccinee	1.1 (0.8, 1.6)	.633	—	—
Received MenB-FHbp vaccine dosese
0	1.0		1.0
1	1.8 (1.1, 2.8)	.014	1.5 (1.0, 2.4)	.074
2	1.5 (1.0, 2.1)	.037	1.4 (1.0, 2.1)	.082
3	1.8 (1.1, 2.9)	.015	1.6 (0.9, 2.7)	.124

A total of 2843 observations from 2014 unique individuals were included in these models.

Abbreviations: MenACWY, quadrivalent meningococcal conjugate vaccine; MenB-FHbp, serogroup B meningococcal factor H binding protein.

^aPrevalence ratios account for repeat participants using generalized estimating equation methods.

^bVariables with significance >0.05 in bivariate models were not included in the multivariable model.

^cIn the past 30 days.

^dIn the past 2 weeks.

^eRefers to vaccine doses received ≥2 weeks prior to date of specimen collection.